Cellectis Achieves 100% Overall Response Rate in Phase 1 Data Set for Allogeneic CAR-T Candidate lasme-cel
Cellectis, a biotechnology company pioneering the allogeneic CAR-T approach, has made significant strides in its clinical trials. In its recent Q4 2025 conference call transcript, the company revealed that its allogeneic CAR-T candidate, lasme-cel, achieved a remarkable 100% overall response rate in the target phase 2 population.
Speaking at the conference call, Dr. André Choulika, Chief Executive Officer of Cellectis, highlighted the importance of this achievement. "Lasme-cel has delivered deep, durable responses in one of the most difficult cancers to treat," he said. This is particularly significant for patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), who have limited therapeutic options.
The company's bridge to transplant strategy is a key aspect of its approach. By targeting CD22, lasme-cel aims to rapidly eliminate residual disease and open the door to bone marrow stem cell transplant, which is currently the only known path to long-term cure for these patients.
The phase 1 data set presented in October at Cellectis's R&D day demonstrated that lasme-cel achieved its impressive results in patients who had already failed other treatments, such as CD19 CAR-T, blinatumomab, and inotuzumab. This is a testament to the product's potential as a game-changer in the treatment of B-ALL.
With this success comes a pivotal phase 2 trial initiated for lasme-cel. The company plans to continue site openings in North America and Europe and enroll expansion in 2026, with the first interim analysis expected in Q4 2026.
The implications of Cellectis's achievements are far-reaching. This allogeneic CAR-T approach has the potential to provide an immediate solution for patients with limited therapeutic options, giving them a chance at a cure that previously seemed impossible. As the company continues its clinical trials and expands its product development status, it is clear that Cellectis is making significant strides in the field of biotechnology.
In addition to lasme-cel, Cellectis has another product candidate, eti-cel, which targets patients with relapsed or refractory non-Hodgkin lymphoma. The company's focus on delivering clinical results for patients who are running out of time is evident in its commitment to advancing these therapies.
As the biotechnology landscape continues to evolve, Cellectis remains at the forefront of innovation, driven by its conviction that gene editing can fundamentally transform how we treat patients in the twenty-first century. With this latest achievement, it is clear that Cellectis is making significant strides towards achieving that vision."
